Patients carrying the *1 allele in combination with another normal function allele may have decreased exposure to dabigatran as compared to patients with at least one no function allele. Other genetic and clinical factors may also affect a patient's exposure to dabigatran. This annotation only covers the pharmacokinetic relationship between CYP3A5 and dabigatran and does not include evidence about clinical outcomes.